🎯 Today's Venture Capital PulseUpdated 3h ago
Beeline Medicines lands $300M Series A to acquire BMS immunology pipeline
Beeline Medicines secured a $300 million Series A led by Bain Capital to purchase Bristol Myers Squibb’s immunology pipeline, which includes an oral TLR7/8 inhibitor for lupus and other candidates targeting IL‑2‑CD25, TYK2, IL‑18 and IL‑10 pathways. The financing coincided with other sizable biotech fundings, such as Oricell’s $110 million CAR‑T raise and Terremoto’s $108 million round.
Also developing:
By the numbers: Slash Financial raises $100M at $1.4B valuation
🚀 Top Venture Capital Headlines
Beeline Raises $300m for BMS Drugs, and Other Biofinancings
Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
pharmaphorum
Accenture Invests in General Robotics to Advance Physical AI-Powered Robotics in Manufacturing and Logistics
International management consultancy Accenture has invested, through Accenture Ventures, in AI-native company General Robotics. General Robotics offers general-purpose robotic intelligence that allows organizations to rapidly deploy and continuously adapt robots of any form, with any AI, for any task. With this investment, Accenture and General Robotics will also partner to help manufacturers, logistics companies and […]
Robotics & Automation News
Swiss HQ QAI Ventures Aims to Partner with India’s Quantum AI Startups
QAI Ventures, a specialist VC firm focused on backing startups in the quantum AI space, is looking to deepen its presence in the Indian market through partnerships with key stakeholders across the ecosystem.
YourStory
Autotech Ventures Expands Into UAE to Drive GCC Auto Commerce Digitization
Autotech Ventures expands into the UAE, targeting early-stage digitization and mobility fintech founders across the GCC, managing nearly $600M to boost the region’s auto commerce ecosystem. The post Autotech Ventures Expands into UAE to drive GCC Auto Commerce Digitization appeared first on The Fintech Times.
The Fintech Times
Spain Plants US$200m Flag in Boston with Debut US Biotech Fund
Spain has launched a US$200m venture capital fund anchored in Boston to help Spanish biotech companies scale in one of the world’s foremost life sciences ecosystem. The initiative includes a new trade office in Massachusetts and around US$57m in public seed capital. The post Spain plants US$200m flag in Boston with debut US biotech fund appeared first on European Biotechnology Magazine.
European Biotechnology
💰 Venture Capital Fundraising
SolvaPay Raises $2.6M Pre‑seed Round Led by Redstone and MS&AD Ventures
Stockholm‑based AI payments platform SolvaPay closed a $2.6 million pre‑seed funding round to build AI‑native payment infrastructure for the emerging agentic commerce market. The round was led by Redstone and MS&AD Ventures, with participation from Antler and Greens Ventures. The capital will accelerate product development, expand the engineering team, and support early adoption among SaaS and API providers.
Wayve Raises $60M From AMD, Arm and Qualcomm Ventures
London-based autonomous vehicle startup Wayve announced a $60 million funding round from chipmakers AMD, Arm and Qualcomm Ventures. The investment will support Wayve's global expansion and development of its AI driver platform for robotaxi fleets, building on its $1.2 bn Series D raise earlier this year. The round values the company at $8.6 bn.
Spektr Raises $20M Series A Led by New Enterprise Associates
Copenhagen‑based fintech compliance startup Spektr announced a $20 million Series A round led by New Enterprise Associates, with participation from Northzone, Seedcamp and PSV Tech. The funding brings total capital raised to just under $26 million and will support expansion into London, New York and further product development. The round was disclosed exclusively to Crunchbase News.
💬 Top Venture Capital Social Posts
The SaaS M&A Report 2026 A Concise Look at the 2026 SaaS M&A Market, the AI-Driven SaaSpocalypse, and the Valuation Shifts Reshaping Software Deals, Private Multiples, and Exit Strategy. The SaaS… | Ryan Allis
The SaaS M&A Report 2026 A concise look at the 2026 SaaS M&A market, the AI-driven SaaSpocalypse, and the valuation shifts reshaping software deals, private multiples, and exit strategy. The SaaS industry entered 2026 in the grip of its most significant market disruption since the 2022 rate-hike correction. What Wall Street traders dubbed the "SaaSpocalypse"—triggered by Anthropic's launch of Claude Cowork on January 12, 2026—erased approximately $1 trillion in aggregate market capitalization from enterprise SaaS stocks in just weeks. Yet beneath the panic lies a more nuanced story. While public SaaS multiples compressed from ~7.0x to ~5.5x and individual stocks like HubSpot fell 39%, the underlying M&A market remained remarkably active. 2025 set records for SaaS deal volume, with 17 mega-deals exceeding $2.5 billion and total announced deal value surpassing $180 billion. Cybersecurity and AI infrastructure dominated. This report covers the full landscape: the record-breaking M&A deals of 2025, the SaaSpocalypse and what it means for valuations, private SaaS multiples entering Q1 2026, the Rule of 40 as the defining metric of this era, and the upcoming mega-IPOs from Anthropic, OpenAI, and SpaceX that will reshape capital markets for years to come. You can read the full SaaS M&A Report 2026 article here: https://lnkd.in/dMtzQ22A If you like data-driven SaaS content like this and want more, apply to join the SaasRise mastermind community for SaaS CEOs and founders in the $1M to $100M ARR. (link in comments below) 👇
Thread by @Kim3wc
Investors are basically telling early-stage founders to figure it out first, then come back for money. I know how that lands, but after a month of conversations with founders, investors, and accelerators - it's hard to argue with the pattern. Investors want to see revenue math so obvious it's undeniable, putting you in a strange position: build far enough to prove you don't need them, then they'd love to talk. Bootstrapping used to be one path, now it feels non-optional for at least a season.
Tweet by @Unitystoakes
I really enjoyed interviewing @a16z 's @julieyoo : Rethinking the Rules: Julie Yoo on Infinite Healthcare, Compound Businesses, and the New Investor Playbook https://t.co/fdIq6NbQ7b cc @startuphealth
